{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:30:56Z","timestamp":1794803456990,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.xcrm.2023.101204","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:31:07Z","timestamp":1695738667000},"page":"101204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Clinical development and management of adverse events associated with FGFR inhibitors"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101204_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101204_bib2","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2023.101204_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2023.101204_bib4","series-title":"BALVERSA\u00ae (Erdafitinib) Tablets, for Oral Use","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101204_bib5","series-title":"PEMAZYRE\u00ae (Pemigatinib) Tablets, for Oral Use","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101204_bib6","series-title":"LYTGOBI\u00ae (Futibatinib) Tablets, for Oral Use. Highlights of Prescribing Information","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101204_bib7","series-title":"FDA Approves Pemigatinib for Relapsed or Refractory Myeloid\/lymphoid Neoplasms with FGFR1 Rearrangement","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101204_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A phase\u00a02\u00a0study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101204_bib9","series-title":"TRUSELTIQ (Infigratinib) Capsules, for Oral Use","year":"2021"},{"key":"10.1016\/j.xcrm.2023.101204_bib10","series-title":"TRUSELTIQ\u00ae (INFIGRATINIB) CAPSULES","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101204_bib11","doi-asserted-by":"crossref","first-page":"S1461","DOI":"10.1016\/j.annonc.2022.10.112","article-title":"76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Park","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib12","doi-asserted-by":"crossref","first-page":"TPS597","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS597","article-title":"FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M\/A)","volume":"38","author":"Javle","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2020.38.6_suppl.489","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1\/3 mRNA expression","volume":"38","author":"Quinn","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101204_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2023.101204_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101204_bib18","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib19","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2023.101204_bib20","doi-asserted-by":"crossref","first-page":"103091","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2023.101204_bib21","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101204_bib22","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2023.101204_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2023.101204_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2023.101204_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib25","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2023.101204_bib26","series-title":"Pemazyre (Pemigatinib) Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.xcrm.2023.101204_bib27","series-title":"Qualifying Notice: Pemazyre","year":"2021"},{"key":"10.1016\/j.xcrm.2023.101204_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101204_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101204_bib32","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2021.39.6_suppl.437","article-title":"Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: results from the dose-finding phase Ib substudy of FIDES-02","volume":"39","author":"Abdul-Karim","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101204_bib35","doi-asserted-by":"crossref","first-page":"P02-02","DOI":"10.1158\/1535-7163.TARG-21-P02-02","article-title":"Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors","volume":"20","author":"Goyal","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2023.101204_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"W\u00f6hrle","year":"2011","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.xcrm.2023.101204_bib37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2020.08.002","article-title":"Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1-3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced\/metastatic urothelial carcinoma","volume":"78","author":"Lyou","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2023.101204_bib38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2023.101204_bib39","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101204_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/IJNRD.S318593","article-title":"Multidisciplinary perspectives of current approaches and clinical gaps in the management of hyperphosphatemia","volume":"14","author":"Vall\u00e9e","year":"2021","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.xcrm.2023.101204_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-16-9","article-title":"The \u201cphosphorus pyramid\u201d: a visual tool for dietary phosphate management in dialysis and CKD patients","volume":"16","author":"D\u2019Alessandro","year":"2015","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.xcrm.2023.101204_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.jrn.2010.06.021","article-title":"Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients","volume":"21","author":"Benini","year":"2011","journal-title":"J.\u00a0Ren. Nutr."},{"key":"10.1016\/j.xcrm.2023.101204_bib43","first-page":"HS18-","article-title":"New pharmacotherapy options for hyperphosphatemia","volume":"41","author":"Stormont","year":"2016","journal-title":"U.S. Pharm."},{"key":"10.1016\/j.xcrm.2023.101204_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nefro.2015.07.002","article-title":"Response to acetazolamide in a patient with tumoral calcinosis","volume":"35","author":"Landini-Enr\u00edquez","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.xcrm.2023.101204_bib45","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/ckj\/sfab078","article-title":"Hypophosphatemia in cancer patients","volume":"14","author":"Adhikari","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.xcrm.2023.101204_bib46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamaophthalmol.2021.3331","article-title":"Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy","volume":"139","author":"Francis","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.xcrm.2023.101204_bib47","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2023.101204_bib48","doi-asserted-by":"crossref","first-page":"A098","DOI":"10.1158\/1535-7163.TARG-17-A098","article-title":"Preliminary results from a phase 1\/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies","volume":"17","author":"Saleh","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2023.101204_bib49","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.jlr.2022.100324","article-title":"Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis","volume":"64","author":"Moreau","year":"2023","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2023.101204_bib50","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/apt.13570","article-title":"Review article: bile acid diarrhoea\u00a0\u2013 pathogenesis, diagnosis and management","volume":"43","author":"Mottacki","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2023.101204_bib51","doi-asserted-by":"crossref","first-page":"A078","DOI":"10.1158\/1535-7163.TARG-19-A078","article-title":"Abstract A078: FIGHT-101: A phase 1\/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies","volume":"18","author":"Subbiah","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2023.101204_bib52","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123003713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123003713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:10:31Z","timestamp":1715047831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123003713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666379123003713"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development and management of adverse events associated with FGFR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101204"}}